Go Deep
Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 24,199 | 12.0 | 1.53 | 0.01 | 580.00 |
| Oct 2026 | 23,608 | 11.6 | 1.48 | 0.01 | 558.30 |
Lincoln Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,772,821,000.0 | 1,872,773,000.0 | 1,663,220,000.0 | 1,633,639,000.0 |
| Net Profit | 362,345,000.0 | 116,346,000.0 | 286,000,000.0 | 199,840,000.0 |
| EPS | 18.1 | 5.8 | 14.3 | 10.0 |
Lincoln Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 6,622,872,000.0 | 6,152,475,000.0 | 5,805,496,000.0 | 5,049,547,000.0 | — |
| Net Profit | 878,938,000.0 | 823,464,000.0 | 933,049,000.0 | 728,993,000.0 | — |
| EPS | 43.9 | 41.1 | 46.6 | 36.4 | — |
Lincoln Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 8,904,039,000.0 | 7,970,059,000.0 | 7,002,904,000.0 | 5,874,202,000.0 | — |
| Total Liabilities | 1,327,719,000.0 | 1,253,373,000.0 | 1,074,545,000.0 | 849,458,000.0 | — |
| Total Equity | 7,576,320,000.0 | 6,716,686,000.0 | 5,928,359,000.0 | 5,024,744,000.0 | — |
Owes vs Owns
Lincoln Pharmaceuticals Limited owed ₹0.15 for every ₹1 it owned in Mar 2026, about the same as ₹0.14 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.15× | 0.16× | 0.15× | 0.14× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Lincoln Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 27.0%Receivables 18.1%Inventory 9.0%Fixed assets (tangible) 22.2%Other assets 23.5%
How it's funded — Mar 2026
Payables 9.5%Other liabilities 4.9%Shareholders' equity 85.1%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 240.7 | 195.7 | 152.4 | 113.8 |
| Receivables | 161.4 | 166.4 | 161.8 | 136.3 |
| Inventory | 80.1 | 78.7 | 77.2 | 70.0 |
| Fixed assets (tangible) | 197.7 | 186.0 | 186.5 | 158.5 |
| Intangible assets | 0.9 | 0.4 | 0.3 | 0.3 |
| Long-term investments | 0.1 | 0.0 | 0.0 | 0.0 |
| Other assets | 209.4 | 169.8 | 122.0 | 108.5 |
| Liabilities & equity | ||||
| Short-term debt | 4.4 | 0.0 | 1.1 | 2.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 84.9 | 84.9 | 72.4 | 50.9 |
| Other liabilities | 43.5 | 40.4 | 33.9 | 32.1 |
| Shareholders' equity | 757.6 | 671.7 | 592.8 | 502.5 |
| Net tangible assets | 756.7 | 671.2 | 592.5 | 502.2 |
Lincoln Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 1,063,595,000.0 | 930,155,000.0 | 632,166,000.0 | 392,619,000.0 | — |
| Investing Activities | -984,069,000.0 | -789,474,000.0 | -573,410,000.0 | -366,426,000.0 | — |
| Financing Activities | 1,589,000.0 | -64,015,000.0 | -51,804,000.0 | -45,013,000.0 | — |